Navigation Links
Shock in Medical Technology

U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant

... The most severe form of dengue disease is dengue shock syndrome, which includes all of the symptoms of ... outside of blood vessels, extensive bleeding, and shock caused by extremely low blood pressure. Dengue shock syndrome most often occurs in children infected ...

U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)

... casualties with severe traumatic hemorrhagic shock without availability of blood transfusions. The ... "Operational Restore Effective Survival in shock (Op RESUS). Op RESUS is designed as a ... have potential to improve survival of hemorrhagic shock casualties. Under a research agreement with ...

Oh, My Aching Back: Give Me a Shot of Ozone

... by small, spongy disks. When these disks are healthy, they act as shock absorbers for the spine and keep the spine flexible. But when a disk is ... be left with too little disk. Taking out a protruding disk may lose the shock absorption that naturally resides between them in the spine," said Murphy, ...

Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients

... surgical researchers found that profound hypothermia effectively treated shock that could not be reversed by standard cardiopulmonary resuscitation, thus ... can preserve organs and prevent death, even in the setting of advanced shock that does not respond to conventional methods of cardiopulmonary ...

UNT Health Science Center's Groundbreaking Research Applied to Protecting Brain After Traumatic Injury

... higher estrogen levels. These current studies of the effects of rapid estrogen administration on patients with traumatic brain injury and hemorrhagic shock will be a test of this proposal. In 1994, Simpkins discovered that estrogens were protective to nerve cells and subsequently has demonstrated ...

IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

... in the 100-day treatment group and took place in France, Belgium and Romania. They were attributed to hemorrhage (one), sepsis (one) or septic shock (two). About CMV CMV belongs to the family of herpes viruses and, as such, is very common among the general population. It is estimated ...

Can Implantable Devices for Heart Failure Help Assess Risk of Future Adverse Events for Heart Failure Patients?

... Additionally, if a potentially life-threatening arrhythmia is detected, the devices in this study were capable of delivering an electrical pulse or shock to correct it. Dr. Whellan explained that the trial observed how well the diagnostic parameters predicted the incidence of clinical events. "We now ...

Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America

... treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating ...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

... increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing reports of anaphylactic shock and angioedema have been reported. TRELSTAR(R) is contraindicated for use in women who are or may become pregnant. For additional information, ...

Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994

... have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia, hemorrhagic shock and inflammation-related diseases. The Company is exploring other receptor-specific therapeutics, including natriuretic peptide receptor A ("NPRA") ...

Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research

... April 16, 2008 -- SNS-314, a potent inhibitor of Aurora kinases, has preclinical anti-activity and induces apoptosis Session: Heat shock Protein Inhibitors, Aurora Kinase and other Mitotic Inhibitors Abstract #5648 8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego ...

Is PCI Safe, Effective After Clot-Busters for Heart Attack?

... evidence of treatment failure. The study will evaluate 30-day combined rates of death, repeat heart attack, recurring ischemia, heart failure and shock in the two groups of patients. "Many hospitals have difficulty getting patients to the cath lab within the recommended 90 minutes, but six hours is ...

Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease

... dedicated to extending the healthspan, the healthy years of each individual's life. The National Institute of Aging designated the Buck a Nathan shock Center of Excellence in the Biology of Aging, one of just five centers in the country. Buck Institute scientists work in an innovative, ...

Initiation of Coverage Informational Review Issued by Scimitar Equity Research

... uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Heat shock proteins (Hsps), also known as stress proteins, are naturally present in the human body and play important roles in the immune system, including ...

News from the American Heart Association

... risk is low. Rescue PCI is recommended for patients who have received fibrinolytic therapy and have any of the following: 1) cardiogenic shock in patients less than 75 years of age who are suitable candidates for revascularization; 2) severe congestive heart failure and/or pulmonary edema; ...

New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns

... enable faster identification of clinically significant changes in a patient's physiologic status, including potentially hypothermia, hypovolemia, shock and/or sepsis. In the study, entitled "Noninvasive Peripheral Perfusion Index as a Possible Tool for Screening for Critical Left Heart Obstruction," ...

ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007

... 16,000 of which are new and just launched in late August. ABR products are available in 43 unique research areas, ranging from Cancer Biology to Heat shock Proteins, and encompassing Signal Transduction, Vision Research, Neurobiology, Steroids & Hormones, Lipid and Fat Metabolism Regulation, ...

Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod

... studies have repeatedly demonstrated semapimod's efficacy in animal models of inflammatory and proliferative diseases, including endotoxic shock and toxicity, pancreatitis, ischemia and stroke, necrotizing enterocolitis, and neointimal formation. Despite early signals of efficacy, the Phase ...

Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies

... accident may cause the thoracic aorta to transect and rupture. Left untreated, TAAs can burst or rupture, leading to severe internal bleeding, shock and death. Approximately half of all TAAs go undetected because patients do not experience symptoms. Presence of symptoms may depend on the location ...

Gilbert Hospital Continues Cutting Edge Treatments

... latest technology in extracorporeal shockwave lithotripsy in the fight against painful kidney stones. This state-of-the-art weapon uses high energy shock waves in a non-invasive procedure to break down kidney stones and other renal-related issues. The Multifunctional Lithotripsy System has been added ...

Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO

... in Chicago, Ill. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently ... flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized ... * A poster entitled, "Inhibition of the Heat shock Protein 90 (Hsp90) chaperone with the novel agent ...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

... Data From the Companies' Novel Heat shock Protein 90 Inhibitor Reveal Further Evidence of ... flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized ... 2007. A poster entitled, "Inhibition of the Heat shock Protein 90 (Hsp90) chaperone with the novel ...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

... in a poster titled, "Phase 2 Trial of Tanespimycin (KOS-953), a Heat shock Protein-90 (Hsp90) Inhibitor in Patients with Metastatic Melanoma," at the ... of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its ...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

... to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Stress proteins, also known as heat shock proteins (Hsps), are naturally present in the human body and play important roles in the immune system, including transporting substances within ...

Study of Drug Therapy for Compulsive Buying Yields a Puzzle, Stanford Researcher Says

... patients improved stably after taking another antidepressant medication, citalopram, in which escitalopram is the active ingredient. "It was a shock that, when we did the trial again with the active ingredient, it didn't work exactly the same way. It should have," said Koran, who also led the 2003 ...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

... Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant ...

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

... Annual Meeting of the American Association for Cancer Research (AACR) in Los Angeles, Calif., April 14-18, 2007. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated as a water-soluble, intravenous formulation in two disease-focused clinical trials ...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

... About Kosan Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant ...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

... About Kosan Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant ...

Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

... data was presented regarding Introgen's other Phase 3 product, INGN 241, indicating that inhibitors of a class of stress proteins called heat shock proteins enhances INGN 241-mediated tumor cell death. These pre-clinical data provide insight into INGN 241 mechanisms of action and identify ...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

... About Kosan Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant ...

Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting

... patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, septic shock and several consumer product areas. RegeneRx is currently sponsoring three Phase 2 chronic dermal wound healing clinical trials and has been cleared ...

Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study

... pivotal Phase III study of 720 patients was designed to evaluate the safety and efficacy of PolyHeme when used to treat patients in hemorrhagic shock following traumatic injuries beginning in the prehospital setting. Treatment began at the scene of injury, continued in the ambulance during ...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

... glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and also induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions differentiate the ...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

... About Kosan Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant ...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

... About Kosan Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant ...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

... About Kosan Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant ...

New Assays to Detect Disseminated Fungal Infections

... is still only 50%. Traditionally, clinicians have been forced to start empiric antifungal therapy in response to any unexplained fever or shock in susceptible patients. It is not uncommon for a disseminated Aspergillus infection to be discovered only at autopsy. Fortunately, a number of ...
Other Contents
(Date:8/28/2014)... 2014A new method for measuring and imaging how quickly ... researchers better understand how drug abuse affects the brain, ... engineering, and lead to better treatment options for recovering ... of researchers from Stony Brook University in New York, ... published today in The Optical Society,s (OSA) open-access journal ...
(Date:8/28/2014)... kilometres of new roads will be built worldwide by ... last wildernesses, where they bring an influx of destructive ... ambitious study has created a ,global roadmap, for prioritising ... the competing demands of development and environmental protection. , ... estimates that natural importance of ecosystems and a ,road-benefits, ...
(Date:8/28/2014)... in homes could pose a significant health risk to people ... Journal of Allergy and Clinical Immunology . , By ... countries, the research has found that the presence of several ... sufferers, as well as increasing the likelihood of developing the ... at the University of Exeter Medical School and is the ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Indoor mold poses health risk to asthma sufferers 2
(Date:8/28/2014)... iFitDress.com, the distinguished wedding dress manufacturer and retailer, has ... . Included in the new range are hundreds of ... provided at deeply discounted prices, from 22 to 62 ... reliable delivery service. All clients from around the world ... As is commonly noted, international customers have different needs ...
(Date:8/28/2014)... Blood's Thicker Than Water is based on a ... in the heart of the city. Raymond E. Blake paints ... how disrespect caused two families to collide with each other ... Yayo Boyz and the M.O.B. Boyz clash in a rain ... in a silent terror. "Guerrilla," AKA "Real," runs his Mob ...
(Date:8/28/2014)... 28, 2014 Millennium Treatment Group has ... in the workplace. A recent report from the ... states that drug abuse is costing employers an estimated ... are addicted to drugs affect their employers and the ... into the workplace, causing expensive problems for their employers, ...
(Date:8/28/2014)... plans its exit strategy from the war, now may be ... health care to veterans, says a Perspective piece in the ... go on doing more of the same is to fail ... and population structure pose in the longer run," said William ... Practice, and David Auerbach, from the RAND Corporation, in the ...
(Date:8/28/2014)... 2014 The Governor of Yucatán, Rolando ... at a press conference; this event is organized by ... of Economy through the National Microenterprise Financing Program ( ... to the 5th at the Convention Center Yucatan Siglo ... a great responsibility for Yucatan to host the 17th ...
Breaking Medicine News(10 mins):Health News:New Selection of Chic Bridesmaid Dresses Available at iFitDress.com 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Drug Use Causes Problems in the Workplace 2Health News:A VA exit strategy 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3
Other TagsOther Tags